Akebia Therapeutics (AKBA) Revenue (2017 - 2026)

Akebia Therapeutics (AKBA) has 10 years of Revenue data on file, last reported at $53.5 million in Q1 2026.

• On a quarterly basis, Revenue fell 6.61% year-over-year to $53.5 million in Q1 2026; TTM through Mar 2026 was $232.4 million, a 25.69% increase from a year earlier, with the FY2025 full-year figure at $236.2 million, up 47.46% from the prior year.
• Revenue for Q1 2026 stood at $53.5 million, down from $57.6 million in the prior quarter.
• Over the last five years, Revenue for AKBA reached as high as $126.4 million in Q2 2022 and fell as low as $76000.0 in Q1 2022.
• Historically, Revenue has averaged $51.5 million across 5 years, with a median of $53.5 million in 2026.
• Across the five-year window, Revenue plunged 99.85% in 2022 and jumped 52538.16% in 2023, its largest moves.
• Year by year, Revenue stood at $55.8 million in 2022, then grew by 0.74% to $56.2 million in 2023, then decreased by 17.26% to $46.5 million in 2024, then gained by 23.93% to $57.6 million in 2025, then retreated by 7.08% to $53.5 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $53.5 million in Q1 2026, $57.6 million in Q4 2025, and $58.8 million in Q3 2025.